Haemonetics Stock Working Capital

HAE Stock

USD 94.40 1.07 1.15%

Haemonetics fundamentals help investors to digest information that contributes to Haemonetics' financial success or failures. It also enables traders to predict the movement of Haemonetics Stock. The fundamental analysis module provides a way to measure Haemonetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Haemonetics stock.

	Last Reported	Projected for Next Year
Net Working Capital	595.6 M	380.9 M
Change In Working Capital	23 M	24.1 M
Working Capital	0.00	0.00

The current year's Change In Working Capital is expected to grow to about 24.1 M, whereas Net Working Capital is forecasted to decline to about 380.9 M.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Haemonetics Company Working Capital Analysis

Haemonetics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Haemonetics Working Capital

517.91 M

Most of Haemonetics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Haemonetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Haemonetics Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Haemonetics is extremely important. It helps to project a fair market value of Haemonetics Stock properly, considering its historical fundamentals such as Working Capital. Since Haemonetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Haemonetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Haemonetics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.61	0.86	0.24	0.91	0.59	0.96	0.97	0.04	0.92	-0.6	0.57	0.91	0.97	0.52	0.3	-0.83	0.92	0.74	0.59	-0.32	-0.56	0.69	-0.78	0.69	-0.6
Total Stockholder Equity	0.61		0.29	0.63	0.59	0.87	0.44	0.63	0.13	0.59	-0.85	0.64	0.35	0.53	0.77	-0.03	-0.37	0.38	0.44	0.39	-0.57	-0.28	0.34	-0.18	0.23	0.06
Net Debt	0.86	0.29		-0.1	0.69	0.33	0.95	0.75	0.04	0.86	-0.23	0.61	0.94	0.92	0.39	0.65	-0.94	0.94	0.73	0.61	-0.21	-0.58	0.68	-0.81	0.71	-0.51
Retained Earnings	0.24	0.63	-0.1		0.18	0.36	0.01	0.25	-0.16	0.31	-0.56	0.1	0.04	0.2	0.26	-0.39	0.08	0.06	-0.31	0.24	-0.24	0.23	-0.13	0.2	-0.35	-0.02
Accounts Payable	0.91	0.59	0.69	0.18		0.7	0.84	0.93	0.12	0.71	-0.63	0.59	0.75	0.82	0.6	0.28	-0.62	0.77	0.74	0.34	-0.35	-0.55	0.64	-0.6	0.66	-0.59
Net Receivables	0.59	0.87	0.33	0.36	0.7		0.46	0.64	0.14	0.44	-0.79	0.72	0.37	0.46	0.81	0.16	-0.33	0.39	0.57	0.21	-0.56	-0.37	0.39	-0.14	0.38	0.0
Total Liab	0.96	0.44	0.95	0.01	0.84	0.46		0.91	0.04	0.89	-0.4	0.55	0.96	0.98	0.41	0.44	-0.91	0.97	0.8	0.62	-0.21	-0.58	0.76	-0.88	0.79	-0.61
Total Current Assets	0.97	0.63	0.75	0.25	0.93	0.64	0.91		0.05	0.84	-0.66	0.48	0.84	0.91	0.46	0.13	-0.74	0.85	0.72	0.52	-0.3	-0.5	0.68	-0.74	0.69	-0.61
Short Term Debt	0.04	0.13	0.04	-0.16	0.12	0.14	0.04	0.05		0.03	-0.18	0.31	-0.2	0.02	0.2	0.25	-0.09	-0.19	0.22	-0.42	-0.37	0.03	0.12	0.04	-0.16	0.24
Intangible Assets	0.92	0.59	0.86	0.31	0.71	0.44	0.89	0.84	0.03		-0.52	0.57	0.87	0.96	0.43	0.32	-0.91	0.88	0.59	0.72	-0.36	-0.4	0.56	-0.74	0.53	-0.41
Short Term Investments	-0.6	-0.85	-0.23	-0.56	-0.63	-0.79	-0.4	-0.66	-0.18	-0.52		-0.52	-0.28	-0.46	-0.7	0.16	0.29	-0.31	-0.37	-0.11	0.72	0.38	-0.11	0.1	-0.11	0.06
Common Stock	0.57	0.64	0.61	0.1	0.59	0.72	0.55	0.48	0.31	0.57	-0.52		0.46	0.53	0.88	0.72	-0.55	0.48	0.66	0.2	-0.62	-0.54	0.33	-0.2	0.33	0.02
Long Term Debt	0.91	0.35	0.94	0.04	0.75	0.37	0.96	0.84	-0.2	0.87	-0.28	0.46		0.95	0.33	0.43	-0.88	1.0	0.69	0.73	-0.09	-0.55	0.72	-0.86	0.79	-0.65
Good Will	0.97	0.53	0.92	0.2	0.82	0.46	0.98	0.91	0.02	0.96	-0.46	0.53	0.95		0.42	0.36	-0.9	0.96	0.7	0.7	-0.24	-0.5	0.72	-0.84	0.69	-0.58
Property Plant Equipment	0.52	0.77	0.39	0.26	0.6	0.81	0.41	0.46	0.2	0.43	-0.7	0.88	0.33	0.42		0.42	-0.32	0.35	0.61	0.12	-0.63	-0.65	0.3	-0.09	0.28	0.04
Current Deferred Revenue	0.3	-0.03	0.65	-0.39	0.28	0.16	0.44	0.13	0.25	0.32	0.16	0.72	0.43	0.36	0.42		-0.5	0.42	0.51	0.09	-0.21	-0.43	0.33	-0.26	0.34	-0.09
Net Tangible Assets	-0.83	-0.37	-0.94	0.08	-0.62	-0.33	-0.91	-0.74	-0.09	-0.91	0.29	-0.55	-0.88	-0.9	-0.32	-0.5		-0.89	-0.71	-0.7	0.3	0.46	-0.63	0.83	-0.68	0.34
Long Term Debt Total	0.92	0.38	0.94	0.06	0.77	0.39	0.97	0.85	-0.19	0.88	-0.31	0.48	1.0	0.96	0.35	0.42	-0.89		0.7	0.72	-0.11	-0.56	0.72	-0.86	0.78	-0.65
Capital Surpluse	0.74	0.44	0.73	-0.31	0.74	0.57	0.8	0.72	0.22	0.59	-0.37	0.66	0.69	0.7	0.61	0.51	-0.71	0.7		0.35	-0.25	-0.76	0.77	-0.73	0.86	-0.34
Deferred Long Term Liab	0.59	0.39	0.61	0.24	0.34	0.21	0.62	0.52	-0.42	0.72	-0.11	0.2	0.73	0.7	0.12	0.09	-0.7	0.72	0.35		0.08	-0.16	0.55	-0.66	0.57	-0.22
Accumulated Depreciation	-0.32	-0.57	-0.21	-0.24	-0.35	-0.56	-0.21	-0.3	-0.37	-0.36	0.72	-0.62	-0.09	-0.24	-0.63	-0.21	0.3	-0.11	-0.25	0.08		0.31	0.16	-0.15	0.1	-0.36
Short Long Term Debt	-0.56	-0.28	-0.58	0.23	-0.55	-0.37	-0.58	-0.5	0.03	-0.4	0.38	-0.54	-0.55	-0.5	-0.65	-0.43	0.46	-0.56	-0.76	-0.16	0.31		-0.42	0.47	-0.59	0.35
Cash And Equivalents	0.69	0.34	0.68	-0.13	0.64	0.39	0.76	0.68	0.12	0.56	-0.11	0.33	0.72	0.72	0.3	0.33	-0.63	0.72	0.77	0.55	0.16	-0.42		-0.84	0.85	-0.46
Net Invested Capital	-0.78	-0.18	-0.81	0.2	-0.6	-0.14	-0.88	-0.74	0.04	-0.74	0.1	-0.2	-0.86	-0.84	-0.09	-0.26	0.83	-0.86	-0.73	-0.66	-0.15	0.47	-0.84		-0.85	0.62
Net Working Capital	0.69	0.23	0.71	-0.35	0.66	0.38	0.79	0.69	-0.16	0.53	-0.11	0.33	0.79	0.69	0.28	0.34	-0.68	0.78	0.86	0.57	0.1	-0.59	0.85	-0.85		-0.49
Capital Stock	-0.6	0.06	-0.51	-0.02	-0.59	0.0	-0.61	-0.61	0.24	-0.41	0.06	0.02	-0.65	-0.58	0.04	-0.09	0.34	-0.65	-0.34	-0.22	-0.36	0.35	-0.46	0.62	-0.49

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Haemonetics

Working Capital Over Time

Haemonetics Capital Surpluse

Capital Surpluse

516.59 Million

At present, Haemonetics' Capital Surpluse is projected to increase significantly based on the last few years of reporting.

According to the company's disclosures, Haemonetics has a Working Capital of 517.91 M. This is 21.67% higher than that of the Health Care Equipment & Supplies sector and 11.86% lower than that of the Health Care industry. The working capital for all United States stocks is 64.96% higher than that of the company.

Haemonetics Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Haemonetics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Haemonetics could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics of similar companies.

Haemonetics is currently under evaluation in working capital category among related companies.

Haemonetics Fundamentals

	Return On Equity	0.15
	Return On Asset	0.0612
	Profit Margin	0.1 %
	Operating Margin	0.16 %
	Current Valuation	5.47 B
	Shares Outstanding	50.79 M
	Shares Owned By Insiders	0.76 %
	Shares Owned By Institutions	99.24 %
	Number Of Shares Shorted	2.24 M
	Price To Earning	50.35 X
	Price To Book	4.59 X
	Price To Sales	3.41 X
	Revenue	1.17 B
	Gross Profit	530.77 M
	EBITDA	249.34 M
	Net Income	115.4 M
	Cash And Equivalents	284.47 M
	Cash Per Share	4.79 X
	Total Debt	765.89 M
	Debt To Equity	1.12 %
	Current Ratio	2.73 X
	Book Value Per Share	18.57 X
	Cash Flow From Operations	273.06 M
	Short Ratio	5.08 X
	Earnings Per Share	2.46 X
	Price To Earnings To Growth	1.63 X
	Target Price	105.57
	Number Of Employees	3.03 K
	Beta	0.36
	Market Capitalization	4.79 B
	Total Asset	1.93 B
	Retained Earnings	253.17 M
	Working Capital	517.91 M
	Current Asset	488.09 M
	Current Liabilities	185.55 M
	Net Asset	1.93 B

About Haemonetics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Haemonetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Haemonetics Piotroski F Score and Haemonetics Altman Z Score analysis.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Haemonetics Stock analysis

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.

	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	CEOs Directory Screen CEOs from public companies around the world
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.05)

Earnings Share

2.46

Revenue Per Share

25.092

Quarterly Revenue Growth

0.101

Return On Assets

0.0612

The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Haemonetics Stock Working Capital

Haemonetics Company Working Capital Analysis

Working Capital

Current Assets

-

Current Liabilities

Current Haemonetics Working Capital

Haemonetics Working Capital Driver Correlations

Haemonetics Capital Surpluse

Capital Surpluse

516.59 Million

Haemonetics Working Capital Peer Comparison

Haemonetics Fundamentals

About Haemonetics Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Haemonetics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY